|
Neonatal Intensive Care Drug Manual
|
| bet | 351/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Metoclopramide
Revision Date :23-12-2020
|
Approved: TC, KOH
|
Indication :
|
To facilitate gastric emptying and gastrointestinal motility. May improve feeding intolerance. Use in gastroesophageal reflux patients is controversial.
(Also used to enhance lactation--10 mg every 8 hours.)
|
Dose :
|
0.033 to 0.1 mg/kg/dose
|
Interval :
|
8 hourly.
|
Route :
|
Oral
I.V.
|
Total Daily Dose :
|
Do not exceed 0.3 mg/kg/day.
|
Comments :
|
Toxicity causes extrapyramidal side effects – dystonia, oculogyric crises, torticollis, stridor, dyspnoea. Effects can be reversed with diphenhydramine.
Contraindicated in patients when stimulation of gastrointestinal motility may be harmful (eg, presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation)
|
Supplied as :
|
Syrup 1 mg/ml.
I.V. solution 5 mg/ml.
|
Dilution :
|
Use syrup as supplied.
I.V. - dilute 1 ml IV solution with 4 ml NS = 1 mg/ml.
|
Stability :
|
Discard ampoule once opened.
|
Storage :
|
IV-A dilution made with preservative-free NS is stable for 24 hours at room temperature under normal light or for 48 hours if protected from light
Oral preparation-Stable for 4 weeks at room temperature.
|
Compatibility:
|
Acyclovir, aminophylline, atropine, caffeine citrate, clindamycin, dexamethasone, 5% Dextrose, fentanyl, fluconazole, heparin, hydrocortisone, insulin, lidocaine, linezolid, meropenem, midazolam, morphine, multivitamins, normal saline, piperacillin/tazobactam, potassium chloride, potassium phosphate, prostaglandin E1, ranitidine, remifentanil, TPN, and zidovudine
|
Incompatibility :
|
Ampicillin, calcium gluconate, cephalothin, chloramphenicol, erythromycin, frusemide, penicillin, propofol, sodium bicarbonate.
|
Serum Levels :
|
|
References
Metoclopramide. In: NeoFax® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com/ (cited: 23-12-2020)
Product Information: Metoclopramide hydrochloride intravenous, intramuscular injection, metoclopramide hydrochloride intravenous, intramuscular injection. Fresenius Kabi (per DailyMed), Lake Zurich, IL, 2016
Original version Date: 9/1/2014
|
Author: NMF Consensus Group
|
Current Version number: 2
|
Version Date: 23/12/2020
|
Risk Rating: Low
|
Due for Review: 23/12/2025
|
Approved by: DTC
|
Approval Date: TBA
|
|
| |
